About
Dr Lee is a cancer epigeneticist, leading the Epigenetics and Disease Group at QIMR Berghofer. He is also an Adjunct Associate Professor at University of Queensland and Queensland University of Technology. Dr Lee completed his BSc (Molecular Pathology) at UNSW and his doctoral studies at University of Sydney studying the in vivo role of growth factors in breast cancer. Postdoctoral training at Dana Farber Cancer Institute/Harvard Medical School, Boston, allowed him to study the transcriptional role of cyclin D1 and estrogen receptor in breast cancer as part of a NIH program grant headed by Professor Bob Weinberg at the Whitehead Institute, MIT. As a senior research scientist at Seoul National University, Korea, Dr Lee gained extensive experience within the field of cancer epigenetics and transcriptional regulation. He has expertise in an array of epigenetic and molecular techniques including genome-wide analysis (RNA-seq and ChIP-seq). These techniques and expertise in epigenetics allowed him to focus on epigenetic regulation of tumour suppressors and oncogenes in breast cancer metastasis. Dr Lee has published several papers in high impact international journals including Molecular Cell (4), PNAS (2), AJHG (3), Nature Genetics, Immunity and Cell Reports. Dr Lee has two patents currently active and he is collaborating with pharmaceutical enterprises to develop novel therapeutics for several cancer types.